Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

Z. Hel, W. P. Tsai, A. Thornton, J. Nacsa, L. Giuliani, E. Tryniszewska, M. Poudyal, D. Venzon, X. Wang, J. Altman, David Watkins, W. Lu, A. Von Gegerfelt, B. K. Felber, J. Tartaglia, G. N. Pavlakis, G. Franchini

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8+ and CD4+ T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4+ and CD8+ T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8+ T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of sub-dominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.

Original languageEnglish
Pages (from-to)7180-7191
Number of pages12
JournalJournal of Immunology
Volume167
Issue number12
StatePublished - Dec 15 2001
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
T-Lymphocytes
DNA
Macaca
HIV-1
Epitopes
Vaccines
env Gene Products
Poxviridae
Combined Vaccines
gag Gene Products
AIDS Vaccines
Viruses

ASJC Scopus subject areas

  • Immunology

Cite this

Hel, Z., Tsai, W. P., Thornton, A., Nacsa, J., Giuliani, L., Tryniszewska, E., ... Franchini, G. (2001). Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. Journal of Immunology, 167(12), 7180-7191.

Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. / Hel, Z.; Tsai, W. P.; Thornton, A.; Nacsa, J.; Giuliani, L.; Tryniszewska, E.; Poudyal, M.; Venzon, D.; Wang, X.; Altman, J.; Watkins, David; Lu, W.; Von Gegerfelt, A.; Felber, B. K.; Tartaglia, J.; Pavlakis, G. N.; Franchini, G.

In: Journal of Immunology, Vol. 167, No. 12, 15.12.2001, p. 7180-7191.

Research output: Contribution to journalArticle

Hel, Z, Tsai, WP, Thornton, A, Nacsa, J, Giuliani, L, Tryniszewska, E, Poudyal, M, Venzon, D, Wang, X, Altman, J, Watkins, D, Lu, W, Von Gegerfelt, A, Felber, BK, Tartaglia, J, Pavlakis, GN & Franchini, G 2001, 'Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen', Journal of Immunology, vol. 167, no. 12, pp. 7180-7191.
Hel, Z. ; Tsai, W. P. ; Thornton, A. ; Nacsa, J. ; Giuliani, L. ; Tryniszewska, E. ; Poudyal, M. ; Venzon, D. ; Wang, X. ; Altman, J. ; Watkins, David ; Lu, W. ; Von Gegerfelt, A. ; Felber, B. K. ; Tartaglia, J. ; Pavlakis, G. N. ; Franchini, G. / Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. In: Journal of Immunology. 2001 ; Vol. 167, No. 12. pp. 7180-7191.
@article{9555257cc09c4eb7a56ea5f3f985d2b8,
title = "Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen",
abstract = "T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8+ and CD4+ T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4+ and CD8+ T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8+ T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of sub-dominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.",
author = "Z. Hel and Tsai, {W. P.} and A. Thornton and J. Nacsa and L. Giuliani and E. Tryniszewska and M. Poudyal and D. Venzon and X. Wang and J. Altman and David Watkins and W. Lu and {Von Gegerfelt}, A. and Felber, {B. K.} and J. Tartaglia and Pavlakis, {G. N.} and G. Franchini",
year = "2001",
month = "12",
day = "15",
language = "English",
volume = "167",
pages = "7180--7191",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Potentiation of Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

AU - Hel, Z.

AU - Tsai, W. P.

AU - Thornton, A.

AU - Nacsa, J.

AU - Giuliani, L.

AU - Tryniszewska, E.

AU - Poudyal, M.

AU - Venzon, D.

AU - Wang, X.

AU - Altman, J.

AU - Watkins, David

AU - Lu, W.

AU - Von Gegerfelt, A.

AU - Felber, B. K.

AU - Tartaglia, J.

AU - Pavlakis, G. N.

AU - Franchini, G.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8+ and CD4+ T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4+ and CD8+ T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8+ T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of sub-dominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.

AB - T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8+ and CD4+ T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4+ and CD8+ T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8+ T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of sub-dominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.

UR - http://www.scopus.com/inward/record.url?scp=0035892889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035892889&partnerID=8YFLogxK

M3 - Article

VL - 167

SP - 7180

EP - 7191

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -